Holo-TC study results could boost B12 assay market
This article was originally published in Clinica
Axis-Shield (Dundee, UK) has restated its belief that its Holo-TC assay for the biologically active part of the vitamin B12 molecule could replace serum B12 as a standard marker for Alzheimer's disease. The statement follows the completion of a joint study between the Universities of Oxford (UK) and Bergen (Norway), which confirmed that low serum levels of Holo-TC are associated with the disease.
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.